课题基金 / 基金详情

项目摘要

项目成果

Benjamin L Wolozin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): TDP-43 was recently identified as one of the major proteins that accumulate in inclusions in sporadic Amyotrophic Lateral Sclerosis (ALS) and in Fronto-temporal dementia with ubiquitin inclusions (FTLD- U). Abnormalities in TDP-43 biology are sufficient to cause neurodegenerative disease because mutations in TDP-43 are linked to familial ALS, which suggests that TDP-43 is linked directly to the disease process. The work in this grant proposal will build on our discovery that TDP-43 regulates the translational response to stress. Neurons respond to stresses, such as occur in neurodegenerative diseases, by entering a state of translational arrest. Translationally silenced mRNA is sequestered into inclusions termed stress granules (SG), which are composed of an mRNA and RNA binding proteins, such as TIA-1. Inclusions composed of SGs are intriguing because of their dynamic nature. The proteins that nucleate SGs have the ability to reversibly aggregate partly because they contain aggregation prone polyglutamine and prion domains. TDP-43 is also a RNA binding protein. Our research demonstrates that TDP-43 co-localizes with SGs, and is essential for SG formation. Disease related mutations in TDP-43 appear to enhance SG formation, and conversely, agents that inhibit SG formation rapidly disaggregate TDP-43 inclusions. Our data also suggests that translational inhibitors can suppress or even rapidly disperse TDP-43 inclusions. We hypothesize that SGs contribute to formation of TDP-43 inclusions, such as occur in FTLD-U and ALS, and that inhibiting SGs can inhibit formation of TDP-43 inclusions. Aim 1 of this proposal will move our work from cell lines to primary neurons. Our preliminary work has been performed in cell lines such as human BE-M17 neuroblastoma cells, but the regulation of SGs differs in neurons. We will determine the types of conditions that stimulate formation of TDP-43 inclusions in primary cortical and spinal motor neuron cultures. We will also determine how mutations in TDP-43 affect inclusion formation. Aim 2 will identify the structural domains of TDP-43 inclusion formation and suppression/dispersion of TDP-43 inclusions. This work will identify the conditions and domains on TDP-43 that one can target to develop therapeutic approaches that can suppress or reverse TDP-43 inclusions and possibly treat ALS and FTLD-U. PUBLIC HEALTH RELEVANCE: This project investigates TDP-43, which is one of the major proteins that accumulate in Amyotrophic Lateral Sclerosis (ALS) and in Fronto-temporal dementia with ubiquitin inclusions (FTLD-U). We will determine the types of conditions that stimulate aggregation of TDP-43 and novel methods to prevent or reverse TDP-43 aggregation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of N6-methyladenosine modified RNA in Alzheimer's disease: Equipment Supplement
  • 批准号:
    10790273
  • 项目类别:
  • 资助金额:
    $5.6万
  • 财政年份:
    2022
  • 负责人:
    Benjamin L Wolozin
  • 依托单位:
The role of N6-methyladenosine modified RNA in Alzheimer's disease
  • 批准号:
    10591151
  • 项目类别:
  • 资助金额:
    $80.65万
  • 财政年份:
    2022
  • 负责人:
    Benjamin L Wolozin
  • 依托单位:
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology
  • 批准号:
    10436271
  • 项目类别:
  • 资助金额:
    $76.93万
  • 财政年份:
    2021
  • 负责人:
    Benjamin L Wolozin
  • 依托单位:
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology
  • 批准号:
    10682571
  • 项目类别:
  • 资助金额:
    $61.51万
  • 财政年份:
    2021
  • 负责人:
    Benjamin L Wolozin
  • 依托单位:
国内基金
海外基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
  • 批准号:
    22077118
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    高楠
  • 依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
  • 批准号:
    81870666
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    王海燕
  • 依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
  • 批准号:
    81601123
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2016
  • 负责人:
    都瑾
  • 依托单位:
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
  • 批准号:
    30971012
  • 项目类别:
    面上项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2009
  • 负责人:
    刘瑞田
  • 依托单位: